Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 39Lung Neoplasms 38Squamous Cell Carcinoma of Head and Neck 23Uterine Cervical Neoplasms 18Head and Neck Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 13Central Nervous System Neoplasms 13Stomach Neoplasms 12Mesothelioma, Malignant 12Neuroblastoma 11Oropharyngeal Neoplasms 10Lymphoma 10Esophageal Neoplasms 10Ovarian Neoplasms 9Carcinoma, Ovarian Epithelial 9Urinary Bladder Neoplasms 8Adenocarcinoma of Lung 8Testicular Neoplasms 7Mouth Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Laryngeal Neoplasms 7Testicular Germ Cell Tumor 6Lymphoma, Large-Cell, Immunoblastic 6Carcinoma 6Astrocytoma 6Teratoma 5Small Cell Lung Carcinoma 5Peritoneal Neoplasms 5Oligodendroglioma 5

Interventions

Trastuzumab 2Streptozocin 2tipifarnib 1romidepsin 1Sorafenib 1Pantoprazole 1Oxaliplatin 1Omeprazole 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Fluorouracil 1Floxuridine 1Doxorubicin 1Cisplatin 1Capecitabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gastrinoma × Cisplatin × Clear all
NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡